What is Esperion Therapeutics's D&A?

Esperion Therapeutics (ESPR) reported D&A of $27K in Q1 2026.

How has Esperion Therapeutics's D&A changed year-over-year?

Esperion Therapeutics's D&A increased by 3.8% year-over-year, from $26K to $27K.

What is the long-term trend for Esperion Therapeutics's D&A?

Over 4 years (2021 to 2025), Esperion Therapeutics's D&A has grown at a -35.6% compound annual growth rate (CAGR), from $612K to $105K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Esperion Therapeutics ESPR D&A

D&A at other companies

AmgenAMGN

$1.12B-19.5%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

NewAmsterdam Pharma CompanyNAMS

$62K+19.2%

Lexicon PharmaceuticalsLXRX

$110K-37.5%

Zevra Therapeutics, Inc.ZVRA

$368K-77.7%

Eton Pharmaceuticals, Inc.ETON

$1.13M+11.6%

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's D&A?: Esperion Therapeutics (ESPR) reported D&A of $27K in Q1 2026.
How has Esperion Therapeutics's D&A changed year-over-year?: Esperion Therapeutics's D&A increased by 3.8% year-over-year, from $26K to $27K.
What is the long-term trend for Esperion Therapeutics's D&A?: Over 4 years (2021 to 2025), Esperion Therapeutics's D&A has grown at a -35.6% compound annual growth rate (CAGR), from $612K to $105K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.